- Case report
- Open Access
- Open Peer Review
Brain metastases as primary manifestation of a melanocytic malignant peripheral nerve sheath tumor in a 60-year-old man
© Tilgner et al; licensee BioMed Central Ltd. 2007
- Received: 04 September 2006
- Accepted: 16 January 2007
- Published: 16 January 2007
Malignant peripheral nerve sheath tumors are rare tumor entities that originate from peripheral nerve sheaths and have an unfavorable prognosis. Metastatic spread to the cerebral parenchyma is absolutely rare. This case report describes the clinical course in a 60-year-old man whose tumor came to medical attention because of a seizure.
Magnetic resonance imaging demonstrated two intracerebral lesions. The symptomatic lesion was removed microneurosurgically and histology demonstrated a metastasis from a malignant peripheral nerve sheath tumor. Postoperatively, whole-brain irradiation was performed. The primary tumor was identified in the area of the sciatic nerve on the right. Follow-up 14 months after resection showed that there was no progression of the intracerebral lesions but an increase in size and number of distant metastases.
There are no generally accepted guidelines for the treatment of malignant peripheral nerve sheath tumors with cerebral metastases. This case report presents and discusses one possible therapeutic approach. Due to the poor overall prognosis, the least invasive therapy should be chosen.
- Brain Metastasis
- Malignant Peripheral Nerve Sheath Tumor
- Electron Microscopy Investigation
- Cerebral Metastasis
- Left Frontal Lobe
The term "malignant peripheral nerve sheath tumor"(MPNST) comprises various entities including malignant schwannoma, neurofibrosarcoma, and neurogenic sarcoma. MPNSTs are rare with an incidence of 1:100,000. About half of the tumors occur in patients with type I neurofibromatosis[1, 2]. Interestingly, about 10% of patients have a history of radiotherapy. Reliable data on survival is not available due to the rarity of the tumor and the heterogeneous patient population. One study reports a 5-year survival rate of 64% as compared with 72–78% for sarcomas. The prognosis appears to depend on the tumor size (more unfavorable for tumors >5 cm), the histological grade and the resection margin in patients operated on. There are two different grading classifications: One depends on the World Health Organisation (WHO) classification for soft-tissue tumors with a grading scale from I-III, the other one on the WHO classification for tumors of the nervous system with a grading scale IIIandIV[5, 6]. The cell type from which MPNSTs are derived has not been yet identified. According to the WHO definition, MPNSTs are tumors that arise from a peripheral nerve or histologically show nerve sheath differentiation. MPNST is a highly aggressive tumor with a high rate of local recurrence and pulmonary and visceral metastatic spread. Brain metastases are extremely rare and only eleven cases have been published since 1963. We report the case of a 60-year-old man presenting with the initial symptom of a focal seizure and in whom magnetic resonance imaging (MRI) demonstrated two intracerebral lesions.
The patient's neurological status on admission was normal. There were no clues to phakomatosis in the patient's or in the family history. Neither did the clinical findings point in this direction. No further seizures occurred after initiation and starting phenytoin therapy.
Imaging and laboratory study
Initial MRI demonstrated a contrast-enhancing lesion in the left frontal lobe and a smaller lesion in the right frontal lobe (Figure 1A+C). No other focal lesions were identified. Laboratory tests were normal except for elevations of the following parameters: D-dimer level of 254, neuron-specific enolase level of 13.1, and lambda and kappa light chain levels of 1.63 and 4.64, respectively. The CSF cell count and protein content were normal.
Since the lesions had no mass effect, initially a stereotactic biopsy was obtained from the left frontal lesion. Histologically, a semimalignant melanocytoma with the differential diagnosis of a MPNST was diagnosed. The lesion was then removed microneurosurgically. Postoperatively, the patient underwent whole-brain irradiation (30Gy). Due to the advanced stage of the malignancy and to gain control over further intracerebral metastasis, which were not visible on the MRI, no local radiotherapy such as radiosurgery was chosen. No postoperative or radiation-related complications were observed.
Fluorodeoxyglycose positron emission tomography (FDG PET) identified no body lesions except for an area of increased accumulation lateral to the right jugular vein, which corresponded to an enlarged lymph node, suggesting a nodal metastasis on MRI. PET even failed to demonstrate the right frontal lesion that was still present prior to cerebral irradiation. Only whole-body MRI (T2WI) identified several structures of increased signal intensity in the right thigh. One of the lesions was contiguous with the sciatic nerve (Figure 2 and 3). The radiologic criteria were indicative of a peripheral nerve tumor, suggesting that this was the primary tumor. Spinal MRI demonstrated further metastases at the level of S1 and S2 but no relationship to spinal nerves (Figure 4).
The first follow-up examination was performed after 3 months. MRI identified no tumor recurrence in the left frontal lobe and no progression of the lesion on the right (Figure 1B+D). The patient had no clinical or neurological symptoms and suffered no seizures on continuous phenytoin medication (300 mg/day). At the last follow-up 11 months later, MRI showed unchanged cerebral findings and no progression of the lumbar vertebral lesions. However, there was an increase in the size of the cervical lymph node metastasis, and MRI for the first time demonstrated metastases in the area of the right thigh. Nevertheless, the patient continued to be free of neurologic deficits or epileptic seizures and no further therapy was initiated.
The diagnosis of a MPNST is a clinical challenge for the physician regarding treatment options and additional diagnostic steps. In particular, if the tumor has spread into the Central Nervous System. No uniform criteria have been established for the treatment of MPNST outside the central nervous system. However, it is widely agreed that the extent of surgical resection is an important prognostic factor while no definitive data is available on the benefit of postoperative radiotherapy. Irradiation seems to reduce local recurrence but does not affect the overall survival rate. Evidence for any relevant cytotoxic effect of chemotherapy (doxorubicin, ifosfamide) is not available. Chemotherapy is performed only with palliative intent.
Cases of MPNST with brain metastasis
Site of primary tumor
Localization of Brain metastasis
Treatment of brain metastasis
Survival time 2)
D'Agostino, 1963 
White, 1971 
Lumbar spinal nerve
Doi, 1983 
Incomplete resection, irradiation
Hasegawa, 1984 
Thoracolumbar spinal nerve
None (biopsy only)
3 1/2 months
Hirose, 1989 
Resection, irradiation, chemotherapy
D'Angelo, 1991 
Fenzi, 1995 
Haisa, 1996 
Oishi, 2000 
Tsuchiya, 2004 
Medial angle of eye
Matyja, 2004 
MPNST in general has an unfavorable prognosis with a 5-year survival rate of only 64%. Survival is even much shorter in patients with a brain metastasis and is not affected by the therapeutic approach. A definitive appraisal of the situation is difficult because only few patients have been treated so far. One patient survived for 18 months without treatment  whereas another died a few months after total resection of a brain metastasis. In our case, resection and irradiation have so far suppressed local cerebral recurrence for a total of 14 months while there has been progression of the other distant metastases. Given the rapid tumor progression in our case, cautious therapy with little harm to the patient is indicated.
Beside the clinical challenge of a new diagnose MPNST, the pathologist has to deal with a great work up in the beginning to provide the physician with a correct diagnosis. The histological diagnosis of MPNST requires careful differentiation from a number of tumor entities with similar histologic features. In general, MPNST cells have either an epithelioid or spindled architecture with gradual transitions between the two. The spindled type must be carefully differentiated from other spindled-cell soft tissue tumors, in particular fibrosarcoma. An immunoreaction to S-100 as in our case excludes a fibrosarcoma and underlines the close association of MPNST with the nerve sheaths[9, 10]. Another tumor to be considered in the differential diagnosis in our patients was malignant melanoma because some cells were found to contain melanin on microscopic inspection. However, a malignant melanoma could be excluded because there was no immunoreaction to LU-5 (cytokeratin), which is only expressed in some epitheloid variants of melanomas. Whereas vimentin positivity as in this case, occurs also in high malignant melanomas. Nevertheless, evidence of a basal lamina by electron microscopy investigation strongly indicates the tumor as a MPNST by nerve sheath origin. In the case presented here, the tumor was further characterized as a melanocytic MPNST because the melanin-containing cells were found to be positive for HMB45.
Written consent was obtained from the statutory person in charge of the patient for publication of this case report.
- Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986, 57: 2006-2021. 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Perrin RG, Guha A: Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2004, 15: 203-216. 10.1016/j.nec.2004.02.004.View ArticlePubMedGoogle Scholar
- Baehring JM, Betensky RA, Batchelor TT: Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology. 2003, 61: 696-698.View ArticlePubMedGoogle Scholar
- Angelov L, Davis A, O'Sullivan B, Bell R, Guha A: Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery. 1998, 43: 56-64. 10.1097/00006123-199807000-00035.View ArticlePubMedGoogle Scholar
- Fletcher CDM, Sundaram M, Rydholm A, Coindre JM, Singer S: Epidemiology, clinical features, histopathological typing and grading. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by: Fletcher CDM, Mertens F and Unni K. 2002, Lyon, International Agency for Research on Cancer, 12-18.Google Scholar
- Woodruff JM, Louis DN, Kourea HP: Malignant peripheral nerve sheath tumor (MPNST). Pathology and Genetics of Tumours of the Nervous System. Edited by: Kleihues P and Cavenee WK. 2000, Lyon, International Agency for Research on Cancer, 172-174.Google Scholar
- Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997, 350: 1647-1654. 10.1016/S0140-6736(97)08165-8.Google Scholar
- Fenzi F, Moretto G, Zamboni G, Passarin MG, Rizzuto N: Brain metastases from post-radiation malignant peripheral nerve sheath tumour. Ital J Neurol Sci. 1995, 16: 495-498. 10.1007/BF02229328.View ArticlePubMedGoogle Scholar
- Matyja E, Naganska E, Gorski R, Zabek M: Multiple brain metastases from malignant peripheral nerve sheath tumour (MPNST). Folia Neuropathol. 2004, 42: 43-48.PubMedGoogle Scholar
- Kuschner M, Laskin S: Experimental models in environmental carcinogenesis. Am J Pathol. 1971, 64: 183-196.PubMedPubMed CentralGoogle Scholar
- D'AGOSTINO AN, SOULE EH, MILLER RH: Primary malignant neoplasms of nerves (malignant neurilemomas) in patients without manifestations of multiple neurofibromatosis (von Recklinghausen's disease). Cancer. 1963, 16: 1003-1014. 10.1002/1097-0142(196308)16:8<1003::AID-CNCR2820160807>3.0.CO;2-S.View ArticlePubMedGoogle Scholar
- White HR: Survival in malignant schwannoma. An 18-year study. Cancer. 1971, 27: 720-729. 10.1002/1097-0142(197103)27:3<720::AID-CNCR2820270331>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Doi E, Ozaki F, Yabumoto M, Moriwaki H, Hayashi S, Komai N: [Multiple malignant intracerebral schwannomas in von Recklinghausen's disease--report of a case]. No Shinkei Geka. 1983, 11: 93-98.PubMedGoogle Scholar
- Hasegawa H, Bitoh S, Otsuki H, Fujiwara M, Yamamoto T, Kobayashi Y: Catecholamine-secreting malignant schwannoma in a patient with multiple intracranial aneurysms. Case report. J Neurosurg. 1984, 60: 1089-1094.View ArticlePubMedGoogle Scholar
- Hirose T, Sumitomo M, Kudo E, Hasegawa T, Teramae T, Murase M, Higasa Y, Ikata T, Hizawa K: Malignant peripheral nerve sheath tumor (MPNST) showing perineurial cell differentiation. Am J Surg Pathol. 1989, 13: 613-620.View ArticlePubMedGoogle Scholar
- D'Angelo V, Casadei G, Bizzozero L: Cerebral metastasis from an epithelioid malignant schwannoma: case report. Neurosurgery. 1991, 29: 906-909. 10.1097/00006123-199112000-00018.View ArticlePubMedGoogle Scholar
- Haisa T, Kondo T, Shinoura N, Hara T, Nasu M: Malignant schwannoma metastasizing to the dura mater--case report. Neurol Med Chir (Tokyo). 1996, 36: 462-465.View ArticleGoogle Scholar
- Oishi H, Ishii K, Bandou K, Ashida H, Abe M: Malignant schwannoma metastasizing to the parenchyma of the brain--case report. Neurol Med Chir (Tokyo). 2000, 40: 116-119. 10.2176/nmc.40.116.View ArticleGoogle Scholar
- Tsuchiya D, Takamura H, Saito K, Kashiwa H, Maeda K, Yamashita H: Immunohistochemical diagnosis of a rare case of epithelioid malignant peripheral nerve sheath tumor with multiple metastases. Jpn J Ophthalmol. 2004, 48: 565-569. 10.1007/s10384-004-0121-8.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/7/2/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.